Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer

Launched by UNIVERSITY HOSPITAL, BORDEAUX · Jun 3, 2024

Keywords

ClinConnect Summary

The MATAC trial is studying the relationship between a blood condition called Immune Thrombocytopenia (ITP) and certain types of cancer. ITP is when your body has low levels of platelets, which are important for blood clotting. Researchers want to understand how cancer cells might cause the immune system to mistakenly attack platelets, leading to ITP. They believe that if cancer cells express a certain protein, it could trigger this immune response and keep the ITP problem going. The goal is to learn more about this connection to help treat patients with both ITP and cancer.

To participate in this study, you need to be an adult who has been diagnosed with both ITP and cancer at the same time, or have developed ITP within six months of being diagnosed with cancer. There are no specific exclusions, so if you meet these criteria, you might be eligible. If you join the trial, you will undergo tests and assessments to help researchers gather important information. This could potentially lead to better treatments for people facing these conditions together.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients with a definite diagnosis of both ITP and cancer;
• • Synchronous diagnosis of ITP and cancer;
• • Onset of ITP occurring 6 months before or after the diagnosis of cancer.
• Exclusion Criteria:
• • None